Skip to main content
  • Magnetic Resonance-Guided Laser Ablation for the Treatment of Malignant Gliomas: A Series of Six Cases

    Final Number:

    Michael E. Ivan MD, MBS; Christopher Banerjee; Brian Michael Snelling MD; Mike H Berger; Nicholas Ferraro MD; Amanda Wallo; Ricardo Jorge Komotar MD, FAANS

    Study Design:

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2015 Annual Meeting

    Introduction: Magnetic resonance-guided laser-induced thermotherapy (MR-LITT) is a minimally invasive technique that shows promise in neuro-oncology due to its superiority in delivering precise minimally invasive thermal energy with minimal collateral damage. In this analysis we investigate initial data on MR-LITT’s effect on glioblastoma (GBM)

    Methods: 6 patients were identified with recurrent GBM with clear evidence of radiological progression. All patients received MR-LITT and then a follow-up MRI scan at 24 hours post treatment, at one month, and at each subsequent follow up visit. The primary end point of the study was local control of the ablated tumor and overall survival. Secondary endpoints include reporting the volume changes after LITT, and steroid usage.

    Results: 6 LITT treatments were performed on 6 patients with the average age of 57.5years. The average tumor volume was 6.9cm3 and ablation dosage was 12.7Watts. On average, 83.8% of the pretreatment lesion volume was ablated. The mean follow-up time was 33.5 weeks. The median overall survival was 42.6 weeks and the median progression free survival was 28.3 weeks. There is a trend towards improved survival with an ablation >86% however further follow-up is needed to confirm these results. There were no major perioperative complications.

    Conclusions: MR-LITT is a promising technology for glioblastoma treatment. This study demonstrates that MR-LITT is safe and offers several advantages over open surgical treatment in treatment of malignant gliomas. Randomized studies are needed to evaluate its role as a treatment adjunct..

    Patient Care: Minimally invasive cytoreduction via the laser could decrease the risk of reoperation while improving outcome.

    Learning Objectives: Understand the safety and efficacy of LITT in recurrent GBM patients.


We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy